Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.

Sales of Eli Lilly’s diabetes and weight loss drugs fell far short of expectations in the third quarter, leading the juggernaut company to reduce its annual revenue guidance and triggering speculation ...

An injection pen of Zepbound, Eli Lilly’s weight loss drug ... week reported a rare $1.5 billion sales miss for its ...

Eli Lilly stock has soared on a new growth wave driven by its diabetes and obesity care treatments. While this has made profit-taking in Lilly stock tempting, the company has several catalysts ahead.

However, Eli Lily is a fast-growing company, with a price/earnings-to-growth ratio (PEG ratio) of only 0.5. PEGs under 1 are ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained the brightest stars in Lilly's lineup. Mounjaro's sales more than doubled year over year to $3.1 billion. Sales for Zepbound, which ...

We recently compiled a list of the Jim Cramer’s Latest Game Plan: 20 Stocks to Watch. In this article, we are going to take a ...

Novo Nordisk and Eli Lilly are racing to increase production in a weight-loss market estimated to reach at least $100 billion ...